Mast Therapeutics Inc (NYSEMKT:MSTX), a clinical-stage biopharmaceutical company leveraging its molecular adhesion and sealant technology (MAST) platform to develop novel therapies for sickle cell disease, heart failure, and stroke, today announced that it will host its first Analyst & Investor Day on October 7, 2015 at the Palace Hotel in New York City. Mast Therapeutics’ full executive management team will provide an update on its vepoloxamer and AIR001 programs, including:

  • EPIC patient enrollment and blinded demographics, including hydroxyurea use among the study population;
  • EPIC statistical assumptions versus blinded performance, including stratification factors and primary endpoint;
  • Initiation of 150-patient, Phase 2 study of vepoloxamer in chronic heart failure;
  • Progress with two AIR001 Phase 2a studies; and
  • Overview of commercial opportunity and strategy for vepoloxamer in sickle cell disease.

“As a leader in the space, and with less than two quarters until top-line results from EPIC, the largest interventional study ever conducted in sickle cell disease, are announced, we believe this is an opportune time to provide substantive updates on EPIC and our other clinical programs,” said Brian M. Culley, the Company’s Chief Executive Officer. “We also look forward to discussing our ongoing activities to prepare for vepoloxamer’s New Drug Application and our commercialization plans for vepoloxamer in sickle cell disease.” (Original Source)

Shares of Mast Therapeutics closed yesterday at $0.49. MSTX has a 1-year high of $0.63 and a 1-year low of $0.38. The stock’s 50-day moving average is $0.45 and its 200-day moving average is $0.48.

On the ratings front, MSTX has been the subject of a number of recent research reports. In a report issued on September 18, Roth Capital analyst Michael Higgins reiterated a Buy rating on MSTX, with a price target of $3, which represents a potential upside of 512.4% from where the stock is currently trading. Separately, on August 17, Cowen’s Ritu Baral maintained a Buy rating on the stock .

According to, which ranks over 7,500 financial analysts and bloggers to gauge the performance of their past recommendations, Michael Higgins and Ritu Baral have a total average return of 17.4% and 20.3% respectively. Higgins has a success rate of 56.5% and is ranked #600 out of 3766 analysts, while Baral has a success rate of 50.0% and is ranked #68.

Mast Therapeutics Inc is a biopharmaceutical company. The Company is engaged in developing novel therapies for serious or life-threatening diseases with unmet needs. Its pipeline includes MST-188 development programs in adjunctive thrombolytic therapy.